Literature DB >> 3657156

Studies on aromatase inhibition with 4-androstene-3,6,17-trione: its 3 beta-reduction and time-dependent irreversible binding to aromatase with human placental microsomes.

M Numazawa1, M Tsuji, A Mutsumi.   

Abstract

The metabolism of 4-androstene-3,6,17-trione (AT), previously described as a suicide substrate for aromatase, and its irreversible binding to aromatase were studied by using human placental microsomes. AT was rapidly converted into 3 beta-reduced metabolite (3-OHAT) with an enzyme other than aromatase in the microsomes in the presence of NADPH under either aerobic or anaerobic conditions. The conversion was efficiently prevented by a steroid 5 alpha-reductase inhibitor. 3-OHAT was characterized as a competitive (Ki = 6.5 microM) and irreversible inhibitor of aromatase. Both 14C-labeled AT and 3-OHAT were demonstrated to be irreversibly bound to aromatase probably through a sulfur atom of the enzyme in time-dependent manners in the presence of NADPH, being accompanied with time-dependent losses of the enzyme activity. It was shown that the process of an apparent time-dependent loss of aromatase activity caused by AT even under conditions allowing its 3 beta-reduction should principally depend on the action of the parent inhibitor AT itself and not on that of the metabolite 3-OHAT.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3657156     DOI: 10.1016/0022-4731(87)91028-4

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  3 in total

Review 1.  Aromatase inhibitors--mechanisms of steroidal inhibitors.

Authors:  R W Brueggemeier
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

2.  3β,5α,6β-Trihy-droxy-androstan-17-one.

Authors:  L C R Andrade; M J B M de Almeida; J A Paixão; J F S Carvalho; M L Sá E Melo
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-04-07

3.  Effects of eight weeks of an alleged aromatase inhibiting nutritional supplement 6-OXO (androst-4-ene-3,6,17-trione) on serum hormone profiles and clinical safety markers in resistance-trained, eugonadal males.

Authors:  Dan Rohle; Colin Wilborn; Lem Taylor; Chris Mulligan; Richard Kreider; Darryn Willoughby
Journal:  J Int Soc Sports Nutr       Date:  2007-10-19       Impact factor: 5.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.